Prof Leung Wing Hang

Professor Leung is the Director of the Children's Blood and Cancer Centre and a Senior Consultant at KK Women's and Children's Hospital, part of SingHealth. He also serves as a Professor at Duke-NUS Medical School.

Previously, Professor Leung was a faculty member at Johns Hopkins University, where he held the position of Chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital. He also served as the Chair of the Department of Paediatrics at the University of Hong Kong*. 
* Hong Kong Special Administrative Region of the People’s Republic of China (SAR)

He was honored with the title of Distinguished Professor and Chair of the SingHealth Duke-NUS Tan Cheng Lim – CCF Professorship in Paediatric Oncology. 

Throughout his career, Professor Leung has held several significant appointments, including Lead for SingHealth Transplant Research, Director of the Paediatric Bone Marrow Transplantation and Cellular Therapy Centre, and Director of Research at the SingHealth Duke-NUS Transplant Centre.

His research interests focus on the biology of human natural killer cells and T-memory cells, with a particular emphasis on their clinical applications in the treatment of cancer, blood disorders, immune system conditions, and infectious diseases.

• PhD 1998
• MBBS 1988

• Director, KKH Children's Blood and Cancer Centre
• Senior Consultant, Paediatric Haematology/Oncology Service, Department of Paediatric Subspecialties
• Director, Paediatric Bone Marrow Transplant & Cell Therapy Centre
• Professor, Duke-NUS Graduate School of Medicine 

• Biology of human natural killer (NK) cells and T-memory cells.
• Transplant, cell and gene therapy for cancer, blood, immune and infectious diseases

ORCID: https://orcid.org/0000-0002-2996-7229

• The central role of natural killer cells in mediating acute myocarditis after mRNA COVID-19 vaccination. Tsang HW, Kwan MYW, Chua GT, Tsao SSL, Wong JSC, Tung KTS, Chan GCF, Wong ICK, Leung W*, Ip P*. Med.  5(4):335-347.e3, 2024 (*contributed equally as corresponding author). JIF 12.8
• Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, Xie Z, Qiao X, Jiang H, Shao J, Yang F, Ren H, Cao Q, Qian J, Zhang J, An K, Wang J, Luo C, Liang H, Miao Y, Ma Y, Wang X, Ding L, Song L, He H, Shi W, Xiao P, Yang X, Yang J, Li W, Zhu Y, Wang N, Gu L, Chen Q, Tang J, Yang JJ, Cheng C, Leung W*, Chen J*, Lu J*, Li B*, Pui CH*. J Clin Oncol. 41(9):1670-1683, 2023. (*contributed equally as last author). JIF 42.1
• Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, Pan H, Wu J, Brennan R, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana V, Santiago T, Hank JA, Gillies SD, Yu A, Sondel PM, Leung W, Pappo A, Federico SM. J Clin Oncol. 40(4):335-344, 2022. JIF 45.4
• KIR-Favorable TCR-αβ/CD19-Depleted Haploidentical HCT in Children with ALL/AML/MDS: Primary Analysis of PTCTC ONC1401. Pulsipher MA, Ahn KW, Bunin NJ, Lalefar NR, Anderson EJ, Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, Abdel-Azim H. Blood. 140(24):2556-2572, 2022. JIF 20.3
• A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak CC, Mellgren KM, Friend BD, Verneris MR, Leung W, Toporski J, Levine JE, Chewning JH, Wayne AS, Kapoor U, Triplett BM, Schultz KR, Yanik GA, Eapen M. Blood. 137(7):983-993, 2021. JIF 25.7